N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,274 Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
Corneal Endothelial Decompensation · Fuchs' Endothelial Dystrophy
Primary: Graft Failure — 32; 15 eyes
Phase 2 N=7 Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa
Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds
N/A N=21 Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) — 1; 3; 7; 9 Participants
N/A N=40 Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
Fuchs Endothelial Dystrophy · Corneal Edema
Primary: Endothelial Cell Loss — 28; 36 percentage of endothelial cell loss — p=0.10
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=65 Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Fuchs' Endothelial Corneal Dystrophy
Primary: Central Corneal Endothelial Cell Density (ECD) at Week 12 — 530.86; 468.02; 228.05 cells/mm2 — p=0.0065
Phase 2 N=22 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
Fuchs' Corneal Endothelial Dystrophy (FCED)
Primary: Incidence and Severity of Ocular TEAEs. — 3; 6; 1; 1 Participants
Phase 2 N=32 Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
Epidermolysis Bullosa
Primary: Percentage of Participants With Event-free Survival — 67; 80; 50; 29 Percentage of participants
N/A N=34 Study of Cellutome System for Treatment of Individual Lesions in EB Pts
Epidermolysis Bullosa
Primary: Percentage of Grafts Successfully Treated — 78 Percentage of grafts
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
Phase 2 N=17 MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
Epidermolysis Bullosa
Primary: Event-free Survival — 4; 2; 1 Count of Participants
Phase 3 N=239 Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
Progressive Keratoconus
Primary: Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax — -0.3; 0.6 Diopters — p=0.0004
Phase 2 N=264 Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
Fuchs' Dystrophy · Bullous Keratopathy
Primary: Number of Eyes With Immunologic Graft Rejection Episodes — 2; 0 eyes — p=0.17
N/A N=5 Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Corneal Ulcer · Leukoma
Primary: Incidence of Treatment-Emergent Adverse Events — 0 events
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 3 N=29 Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Fuchs Endothelial Dystrophy
Primary: Change in Central Corneal Thickness — -23; -2 microns
Phase 2 N=10 Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)
Inherited Epidermolysis Bullosa
Primary: Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds' — 8; 0 Wounds — p==0.008
Phase 2 N=6 Gentamicin for RDEB
Recessive Dystrophic Epidermolysis Bullosa
Primary: Increased Expression of Full-length Type VII Collagen as Assessed by Immunofluorescence — 31.8; 28.4; 65.6 C7 Expression (percent of normal skin)
Phase 4 N=70 Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Corneal Endothelial Dystrophy · Corneal Edema
Primary: Immunologic Rejection — 0 Participants
N/A N=135 Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
Keratoconus
Primary: Number of Participants With Complete Healing of Corneal Epithelial Defect at Day 3 — 20; 25 Participants
Phase 2 N=5 Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients
Recessive Dystrophic Epidermolysis Bullosa
Primary: Restoration of Full-length Type VII Collagen as Assessed by Immunofluorescence. — 5; 5; 4; 4 Fluorescence Intensity (MFI) for C7
Phase 2 N=48 Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of Treatment — 8; 6; 7; 7 Participants — p==0.3699
N/A N=26 Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time
Dry Eye
Primary: Difference Between Keratometric Tear Break Up Time (KTBUT) and Fluorescein Tear Break Up Time (FTBUT) — 5.95; 5.39 time in seconds — p=0.074
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
Phase 3 N=130 Corneal Collagen Cross-Linking for Ectasia (CXL)
Ectasia
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -0.5; 0.5 diopters
N/A N=12 A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients
Recessive Dystrophic Epidermolysis Bullosa
Primary: Number of Wounds With Greater Than 90% Wound Closure at 4 Months — 0; 3 Wounds — p=0.21
Phase 2 N=130 Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Corneal Epithelial Disorders
Primary: Number of Participants With Clearing of Corneal Fluorescein Staining at Week 5 at Week 5 — 5; 7; 12 Participants
Phase 1 N=165 Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Corneal Epithelial Defect · Diabetic Retinopathy · Penetrating Keratoplasty
Primary: Patients With Corneal Epithelial Healing Time Within 14 Days — 78; 73 participants
Phase 2 N=7 Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa
Primary: Percent Change of Active Blisters and in Total Blister/Erosion Counts — -29.6 percent change — p=0.82